Wearable Injectors Market size was valued at USD 6.16 billion in 2021 and is expected to reach USD 13.62 billion by 2028, at a CAGR of 12.0% during the forecast period 2022-2028. Wearable Injectors are the drug delivery devices are technologically designed to deliver a large volume drugs to the patients for long durations. Wearable Injectors Market are also called as patch pumps or patch injectors. These injectors are evolved from the traditional syringes, and are designed to make the treatment easier with its single-step delivery mechanism. The device also helps to control the disease in patients and delivers the drug faster and safer manner in the body through parenteral route. These injectors have opened the door of hassle free medication administration for the patients suffering from cancer, cardiovascular diseases, auto-immune diseases, and diabetes. Wearable injectors are user friendly and reduce the need of multiple painful injections and the number of hospital visits. The COVID-19 pandemic’s uncertainty has influenced demand for various therapeutics and wearable drug delivery technologies. Healthcare systems around the world made steps to postpone treatments for diseases like cancer in order to prevent the spread of the infection and safeguard high-risk patients from becoming infected. The dangers for patients receiving care grew as the pandemic progressed. Hospitals, which serve the bulk of patients, also became high-risk areas during the epidemic. To address these issues and provide appropriate care to patients suffering from various ailments, a movement from hospital-based care to home-based care has occurred. As a result of the pandemic, telemedicine and homecare are becoming more popular. As a result, healthcare delivery has shifted from hospitals and clinics to home care settings. In the next years, this is projected to generate considerable growth potential for industry players. Cancer patients have discovered the critical benefits of wearable injectors, such as a reduction in disease progression and suffering, which has resulted in a major surge in their acceptance across the healthcare business. The On-body Injector is typically inserted on the stomach or behind the arm. It is normally administered by a nurse on the last day of each chemotherapy cycle. As a result, one of the key market drivers is the rise in the occurrence of cancer and heart disorders.
In June 2017, Enable Injections Inc. launched a new single, partial or multi-vial/syringe transfer system used to fill its large volume wearable injectors that enables the patients to either use multiple vials or syringes to deliver biologics and high volume drugs subcutaneously.